/
Other
Exercise
13
Pipeline Programs↗
33
Active Trials↗
18
Companies Involved↗
Exercise is an emerging landscape with 13 programs across 18 companies. The most active players are Mezzion Pharma Co. Ltd, Jiangsu Hansoh Pharmaceutical Co., Ltd.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 21
Phase 34
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
12 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
145
clinical trials
Completed94 · 65%
Unknown status13 · 9%
Not yet recruiting13 · 9%
Recruiting12 · 8%
Active, not recruiting6 · 4%
Terminated5 · 3%
Other2 · 1%
Clinical Trials
Trial Activity
145 trials
U-LABA/ICS Effects on Exercise Performance, Indacaterol
Recruiting·—·N/A·NCT06067100·30 enrolled
Bronchodilators and Lung Mechanics During Exercise in COPD
Recruiting·—·Phase 4·NCT06825013·25 enrolled
U-LABA/ICS Effects on Exercise Performance, Vilanterol
Recruiting·—·N/A·NCT06066606·30 enrolled
Kinesthetic Exercises on Adults
Active, not recruiting·—·N/A·NCT07417748·40 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)